SGLT-2 inhibition in IgA nephropathy: the new standard of care?

Jonathan Barratt; Jürgen Floege

doi:10.1016/j.kint.2021.04.002

SGLT-2 inhibition in IgA nephropathy: the new standard of care?

Kidney Int. 2021 Jul;100(1):24-26. doi: 10.1016/j.kint.2021.04.002. Epub 2021 Apr 17.

Authors

Jonathan Barratt¹, Jürgen Floege²

Affiliations

¹ Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. Electronic address: Jb81@leicester.ac.uk.
² Division of Nephrology and Immunology, Rheinisch Westfälische Technische Hochschule (RWTH) University of Aachen, Aachen, Germany. Electronic address: Juergen.floege@rwth-aachen.de.

PMID: 33878337
DOI: 10.1016/j.kint.2021.04.002

Abstract

Despite supportive measures that slow the rate of progression of chronic kidney disease in IgA nephropathy, many patients still progress to end-stage kidney disease. Currently employed immunosuppressive strategies lack conclusive efficacy data, while there is evidence for treatment-emergent toxicity. A subanalysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Trial, which encompassed 270 patients with a diagnosis of IgA nephropathy, now provides early evidence that dapagliflozin may be a safe and effective addition to current standard of care in IgA nephropathy.

Publication types

Comment

MeSH terms

Benzhydryl Compounds
Glomerulonephritis, IGA* / drug therapy
Glucosides
Humans
Immunosuppressive Agents / adverse effects
Kidney
Renal Insufficiency, Chronic*
Standard of Care

Substances

Benzhydryl Compounds
Glucosides
Immunosuppressive Agents
dapagliflozin